BACKGROUND/AIMS: Differential diagnosis between aggressive osteoblastoma and low grade osteosarcoma may be very difficult or even impossible on a small biopsy. This study was designed to assess the usefulness of immunoexpression of COX-2 and osteocalcin in the differential diagnosis of the two tumour types. METHODS: Immunostaining of COX 2 and osteocalcin were studied in 9 osteoblastomas and 30 osteosarcomas. RESULTS: All osteoblastomas and 11/20 (55%) high-grade osteosarcomas showed COX-2 immunoreactivity. All low grade osteosarcomas were COX-2 negative. COX-2 was significantly higher (p<0.002) in osteoblastomas 9/9 (100%) than in osteosarcomas 13/30 (43%) and in aggressive osteoblastomas versus low grade osteosarcomas (p<0.01). Osteocalcin was found in tumour cells of all osteosarcomas and osteoblastomas and in the osteoid matrix of 84% of osteosarcomas and 78% of osteoblastomas. Strong osteocalcin was significantly higher (p<0.02) in osteoblastomas (78%) than in osteosarcomas (27%). CONCLUSION: COX-2 is a valuable marker in distinction between osteosarcoma and osteoblastoma. Negative COX-2 could confirm the diagnosis of low grade osteosarcoma versus aggressive osteoblastoma. Intensity and distribution of osteocalcin may indicate the degree of osteoblastic differentiation.
BACKGROUND/AIMS: Differential diagnosis between aggressive osteoblastoma and low grade osteosarcoma may be very difficult or even impossible on a small biopsy. This study was designed to assess the usefulness of immunoexpression of COX-2 and osteocalcin in the differential diagnosis of the two tumour types. METHODS: Immunostaining of COX 2 and osteocalcin were studied in 9 osteoblastomas and 30 osteosarcomas. RESULTS: All osteoblastomas and 11/20 (55%) high-grade osteosarcomas showed COX-2 immunoreactivity. All low grade osteosarcomas were COX-2 negative. COX-2 was significantly higher (p<0.002) in osteoblastomas 9/9 (100%) than in osteosarcomas 13/30 (43%) and in aggressive osteoblastomas versus low grade osteosarcomas (p<0.01). Osteocalcin was found in tumour cells of all osteosarcomas and osteoblastomas and in the osteoid matrix of 84% of osteosarcomas and 78% of osteoblastomas. Strong osteocalcin was significantly higher (p<0.02) in osteoblastomas (78%) than in osteosarcomas (27%). CONCLUSION: COX-2 is a valuable marker in distinction between osteosarcoma and osteoblastoma. Negative COX-2 could confirm the diagnosis of low grade osteosarcoma versus aggressive osteoblastoma. Intensity and distribution of osteocalcin may indicate the degree of osteoblastic differentiation.
Authors: Camila Barbosa Amaral; Juliana da Silva Leite; Ana Beatriz Monteiro Fonseca; Ana Maria Reis Ferreira Journal: Mol Biol Rep Date: 2018-07-31 Impact factor: 2.316
Authors: Kivilcim Eren Erdogan; Marina Pacheco; Marco Gambarotti; Giovanna Magagnoli; Marta Sbaraglia; Tommaso Frisoni; Alberto Righi; Angelo Paolo Dei Tos Journal: Virchows Arch Date: 2021-01-28 Impact factor: 4.064
Authors: Lisa Y Pang; Emma L Gatenby; Ayako Kamida; Bruce A Whitelaw; Ted R Hupp; David J Argyle Journal: PLoS One Date: 2014-01-08 Impact factor: 3.240